AbbVie inks up to $2.54 billion DISCO Pharma bispecific platform licensing deal
SentiSense · Published · Updated
AbbVie agreed to pay up to $2.54 billion to develop solid-tumor drugs with Germany's DISCO Pharmaceuticals, including $40 million upfront and up to $2.5 billion in milestones, plus royalties.
ABBV agreed to a research and licensing deal with DISCO Pharmaceuticals worth up to $2.54 billion to develop bispecific cancer therapies for solid tumors. DISCO, based in Germany, receives $40 million upfront and is eligible for up to $2.5 billion in milestone payments, plus tiered royalties on worldwide sales.
The deal targets what DISCO calls AND-gated bispecifics: drugs designed to recognize a cancer cell only when two target proteins are present at the same time, which could spare healthy tissue that carries just one of them. DISCO's platform maps proteins on the surface of cells to find those target pairs. DISCO's CEO Mark Manfredi said the company expects to pick a development candidate in the second half of next year.
The headline figure is mostly contingent. Only the $40 million is paid now, and the rest depends on programs that have not yet reached the clinic, so the agreement is an early-stage pipeline bet rather than a near-term revenue driver.
What to watch: candidate selection in the second half of 2027, any move by AbbVie to license specific programs, and whether the deal is part of a wider AbbVie push into bispecific and targeted solid-tumor drugs.
Related Stocks
Powered by SentiSense - Intelligent Market Analysis